Leflunomide

Clinical Immunotherapeutics

Volumn 6, Issue 4, 1996, Pages 300-305

  Plosker, Greg L ^a   Wagstaff, Antona ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE;

CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0029779669     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259090     Document Type: Review

References (26)

1. Bartlett RR, Anagnostopulos H, Zielinski T, et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathoi 1993 Apr; 14: 381-94
2. Cao WW, Kao PN, Chao AC. et al. Mechanism of the antiproliferative action of leflunomide: A77 1726. the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant !995Nov-Dec: 14(Pt 1): 1016-30
3. Cherwinski HM. Conn RG. Cheung P. et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by in hibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995 Nov: 275: 1043-9
4. Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyrimidine mucleotide biosynthesis. Inflamm Res 1995 Aug; 44: 317-22
5. Morris RE. Mechanisms of action of new immunosuppressive drugs. Kidney Int 1996; 49 Suppl. 53: S26-38
6. Zielinski T. Zeitter D, Mullner S, et al. Leflunomide, a réversible inhibitor of pyrimidine biosynthesis? Inflamm Res 1995: 44 Suppl. 2: S207-8
7. Greene S, Watanabe K. Braatztrulson J, et al. Inhibition ot'dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995 Sep 7; 50: 861-7
8. Atluru S. Atluru D. Evidence that genistein, a protein-tyroxine kinase inhibitor, inhibits CD28 monoclonal-antibodystimulated human T cell proliferation. Transplantation 1991; 51 (2): 448-50
9. Cao W, Chao AC, Morris RE. Leflunomide, a new immunosuppressant, inhibits tvrosine kinase, calcium signaling and DNA synthesis in vascular smooth muscle [abstract]. FASEB J 1994 Mar 15; 8 (Pt i ): 486
10. Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epider mal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993 Nov 15; 334: 161-4
11. Bartlett RR. Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative. H WA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985: 7: 7-18
12. Pasternak RD, Wadopian NS, Wright RN, et al. Disease moditying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions 1987 Aug;2l: 241-3
13. Giant TT, Mikecz K, Bartlett RR, et al. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology 1992 Mar-Apr; 23: 105-16
14. Giant TT, Mikecz K, Brennan F, et al. Suppression of autoimmune responses and intlammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions 1994 Aug: 41 (Spec, issue): C267-70
15. Dimitrijevic M, Kosec D. Popeskovic L, et al. Influence of leflunomide ( HWA 486) on immune system activation in RA (abstract). Rev Esp Reumatol 1993 Jul; 20 Suppl. 1: 398
16. Dimitrijevic M, Stupar N, Pilipovic N. Leflunomide in the treatment of patients with severe rheumatoid arthritis: influence on immunological parameters (abstract]. Clin Exp Rheumatol 1995 Sep-Oct: 13 Suppl. 12: 56
17. Richardson C, Emery P. New therapies for rheumatoid arthritis. BrJCIinPract 1995:49(3): 135-9
18. Fürst DE. Cyclosporin, leflunomide and nitrogen mustard. Baillieres Clin Rheumatol 1995 Nov: 9: 711-29
19. MIadenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995 Nov; 38: 1595-603
20. Carlson RR Newer immunosuppressive drugs and other agents for the treatment of rheumatoid arthritis - an update. Expert Opin Invest Drug 1995 Sep; 4: 853-9
21. Lucien J, Dias VC, LeGatt DF. Blood distribution and singledose pharmacokinetics of leflunomide. Ther Drug Monit 1995 Oct: 17:454-9
22. Roethig H-J. Collins J. Harnisch L. et al. The effect of activated charcoal and cholestyramine on the pharmacokinetics of leflunomide (abstract no. PIII-6S], Clin Pharmacol Ther 1996; 59(2): 204
23. Campion G. Löw-Friedrich I. Oed C. et al. Comparison of different dosing regimens of leflunomide in the treatment of active rheumatoid arthritis (abstract). Scand J Rheumatol 1994 Suppl. 98: abstr. 140
24. Domljan Z, Popovic M. MIadenovic V, et al. Efficacy and safety of leflunomide in the treatment of patients with rheumatoid arthritis (RA) (abstract]. Arthritis Rheum 1993 Sep: 36 Suppl.: 56
25. Dias VC. Lucien J, LeGatt DF, et al. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase highperformance liquid chromatography. Ther Drug Monit 1995 Feb; 17: 84-8
26. Dekleva-Djordjevic J, Radunovic L. Musikic P, et al. Adverse effects of leflunomide treatment in patients with rheumatoid arthritis at the Zemun clinical centre (abstract]. Clin Exp Rheumatol 1995 Sep-Oct: 13 Suppl. 12: 57